Clinical Trial: NCT05888402
Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Information Provided By: | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Last Update Posted: | 2026-02-27 |
Study Overview
Brief Summary
This study is a Phase II study to evaluate the clinical efficacy and safety of Toripalimab combined with chemoradiotherapy for large-volume local advanced non-small cell lung cancer
Official Title
The Efficacy and Safety of Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume (Bulky) Local Advanced Non-small Cell Lung Cancer
Conditions
Local Advanced Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: Toripalimab
- Radiation: Concurrent chemoradiation therapy and consolidation immunotherapy
Other Study ID Numbers
- InTRist
Start Date (Actual)
2023-01-20
Primary Completion Date (Actual)
2024-10-08
Study Completion Date (Estimated)
2026-03-20
Enrollment (Estimated)
50
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Information Provided By: | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Last Update Posted: | 2026-02-27 |
Study Overview
Brief Summary
This study is a Phase II study to evaluate the clinical efficacy and safety of Toripalimab combined with chemoradiotherapy for large-volume local advanced non-small cell lung cancer
Official Title
The Efficacy and Safety of Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume (Bulky) Local Advanced Non-small Cell Lung Cancer
Conditions
Local Advanced Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: Toripalimab
- Radiation: Concurrent chemoradiation therapy and consolidation immunotherapy
Other Study ID Numbers
- InTRist
Start Date (Actual)
2023-01-20
Primary Completion Date (Actual)
2024-10-08
Study Completion Date (Estimated)
2026-03-20
Enrollment (Estimated)
50
Study Type
Interventional
Phase
Phase 2